176 related articles for article (PubMed ID: 33839963)
1. Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib.
Watanabe D; Fujii H; Yamada Y; Matsuhashi N; Makiyama A; Iihara H; Takahashi T; Kiyama S; Kobayashi R; Yoshida K; Suzuki A
Int J Clin Oncol; 2021 Jul; 26(7):1257-1263. PubMed ID: 33839963
[TBL] [Abstract][Full Text] [Related]
2. Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Xu H; Cao D; Zhou D; Zhao N; Tang X; Shelat VG; Samant H; Satapathy SK; Tustumi F; Aprile G; He A; Xu X; Ge W
BMC Cancer; 2023 Oct; 23(1):1006. PubMed ID: 37858207
[TBL] [Abstract][Full Text] [Related]
3. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
[TBL] [Abstract][Full Text] [Related]
4. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Mar; 18(1):e61-e68. PubMed ID: 30348618
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
[TBL] [Abstract][Full Text] [Related]
8. Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma.
Yukimoto A; Hirooka M; Hiraoka A; Michitaka K; Ochi H; Joko K; Imai Y; Watanabe T; Koizumi Y; Yoshida O; Abe M; Hiasa Y
Jpn J Clin Oncol; 2019 Jan; 49(1):42-47. PubMed ID: 30380075
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
Ergun Y; Bal O; Dogan M; Uncu D
J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of albumin-bilirubin score in pancreatic cancer patients after pancreatoduodenectomy with liver metastasis following radiofrequency ablation.
Zhang L; Zhang X; Wu B; Han X; Guo C; Li B; Jing H; Cheng W
Pathol Oncol Res; 2023; 29():1611175. PubMed ID: 37325466
[No Abstract] [Full Text] [Related]
11. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
12. Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients.
Fujita K; Taguchi D; Fukuda K; Yoshida T; Shimazu K; Shinozaki H; Shibata H; Miura M
Invest New Drugs; 2024 Jun; 42(3):252-260. PubMed ID: 38517650
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.
Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661
[TBL] [Abstract][Full Text] [Related]
14. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
[TBL] [Abstract][Full Text] [Related]
16. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
17. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of Preoperative Albumin-Bilirubin Grade in Pancreatic Cancer.
Imamura T; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Uesaka K
Ann Surg Oncol; 2021 Oct; 28(11):6223-6235. PubMed ID: 33486645
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study.
Kim HD; Bang Y; Lee MA; Kim JW; Kim JH; Chon HJ; Kang B; Kang MJ; Kim I; Cheon J; Hwang JE; Kang JH; Byeon S; Hong JY; Ryoo BY; Lim HY; Yoo C
Liver Int; 2020 Oct; 40(10):2544-2552. PubMed ID: 32563213
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]